Higher baseline LTF levels in ES-SCLC patients may predict durable chemoimmunotherapy outcomes, suggesting LTF as a potential biomarker for treatment response. LTF appears to suppress SCLC tumors ...

SCLC patients, particularly with high tumor burden, face significant ATLS risk, despite typically low overall risk in solid tumors. Early recognition and aggressive intervention are crucial, yet ...

"This is the largest retrospective study to assess and demonstrate that immune-related toxicity is positively associated with improved clinical outcomes in patients with ES-SCLC [extensive-stage ...

Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with a high metastatic potential. Treatment with chemotherapy can produce high response rates, but potential relapse rates are ...

The updated results will include additional patients and follow-up from the ongoing trial of ZL-1310 in patients with previously treated ES-SCLC after at least one prior platinum-based ...

Iadademstat, a selective LSD1 inhibitor, is being tested with immune checkpoint inhibitors for extensive-stage SCLC in a phase 1/2 trial. The trial, led by the National Cancer Institute, evaluates ...